Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2017, Article ID 8186275, 7 pages
https://doi.org/10.1155/2017/8186275
Research Article

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis

1Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, China
2Department of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
3Department of Basic and Community Nursing, School of Nursing, Nanjing Medical University, Nanjing 211166, China
4Department of Infectious Diseases, The Jurong People’s Hospital, Jurong 212400, China
5Department of Epidemiology, Medical Institute of Nanjing Army, Nanjing 210002, China

Correspondence should be addressed to Peng Huang; nc.ude.umjn@gnepgnauh and Rongbin Yu; nc.ude.umjn@uynibgnor

Received 14 September 2016; Accepted 20 December 2016; Published 9 January 2017

Academic Editor: Mang Ma

Copyright © 2017 Yinan Yao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Mohd Hanafiah, J. Groeger, A. D. Flaxman, and S. T. Wiersma, “Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence,” Hepatology, vol. 57, no. 4, pp. 1333–1342, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. World Health Organization, Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection, World Health Organization, 2014.
  3. B. Hajarizadeh, J. Grebely, and G. J. Dore, “Epidemiology and natural history of HCV infection,” Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 9, pp. 553–562, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. B. L. Pearlman and N. Traub, “Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more,” Clinical Infectious Diseases, vol. 52, no. 7, pp. 889–900, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Lawitz, A. Mangia, D. Wyles et al., “Sofosbuvir for previously untreated chronic hepatitis C infection,” The New England Journal of Medicine, vol. 368, no. 20, pp. 1878–1887, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Manns, P. Marcellin, F. Poordad et al., “Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial,” The Lancet, vol. 384, no. 9941, pp. 414–426, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. I. M. Jacobson, G. J. Dore, G. R. Foster et al., “Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 384, no. 9941, pp. 403–413, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Zeuzem, T. Berg, E. Gane et al., “Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial,” Gastroenterology, vol. 146, no. 2, pp. 430.e6–441.e6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Osinusi, E. G. Meissner, Y.-J. Lee et al., “Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial,” JAMA - Journal of the American Medical Association, vol. 310, no. 8, pp. 804–811, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Naggie, M. Sulkowski, J. Lalezari, J. Fessel, and K. Mounzer, “Sofosbuvir plus ribavirin for HCV genotype 1–3 infection in HIV coinfected patients (PHOTON-1),” in Proceedings of the 21st Conference on Retroviruses and Opportunistic Infections, pp. 3–6, Boston, Mass, USA, March 2014.
  11. C. Hézode, H. Fontaine, C. Dorival et al., “Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis,” Gastroenterology, vol. 147, no. 1, pp. 132–142.e4, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Lawitz, E. Gane, B. Pearlman et al., “Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial,” The Lancet, vol. 385, no. 9973, pp. 1075–1086, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Sulkowski, C. Hezode, J. Gerstoft et al., “Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial,” The Lancet, vol. 385, no. 9973, pp. 1087–1097, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Forns, S. C. Gordon, E. Zuckerman et al., “Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent,” Journal of Hepatology, vol. 63, no. 3, pp. 564–572, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Zeuzem, R. Ghalib, K. R. Reddy et al., “Grazoprevir–elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial,” Annals of Internal Medicine, vol. 163, no. 1, pp. 1–13, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Poordad, C. Hezode, R. Trinh et al., “ABT-450/r–ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis,” The New England Journal of Medicine, vol. 370, no. 21, pp. 1973–1982, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Afdhal, K. R. Reddy, D. R. Nelson et al., “Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection,” New England Journal of Medicine, vol. 370, no. 16, pp. 1483–1493, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Lawitz, M. S. Sulkowski, R. Ghalib et al., “Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study,” The Lancet, vol. 384, no. 9956, pp. 1756–1765, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. K. E. Sherman, S. D. Rouster, R. T. Chung, and N. Rajicic, “Hepatitis C virus prevalence among patients infected with human immunodefidency virus: a cross-sectional analysis of the US Adult AIDS clinical trials group,” Clinical Infectious Diseases, vol. 34, no. 6, pp. 831–837, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. F. J. Torriani, M. Rodriguez-Torres, J. K. Rockstroh et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients,” New England Journal of Medicine, vol. 351, no. 5, pp. 438–450, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Carrat, F. Bani-Sadr, S. Pol et al., “Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial,” The Journal of the American Medical Association, vol. 292, no. 23, pp. 2839–2848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Rodriguez-Torres, J. Slim, L. Bhatti et al., “Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial,” HIV Clinical Trials, vol. 13, no. 3, pp. 142–152, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. S. J. Hadziyannis, H. Sette Jr., T. R. Morgan et al., “Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Afdhal, S. Zeuzem, P. Kwo et al., “Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection,” The New England Journal of Medicine, vol. 370, no. 20, pp. 1889–1898, 2014. View at Publisher · View at Google Scholar · View at Scopus